News Sentiment

PEPG sentiment intelligence

PepGen Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.34 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+33.0% over one week, +59.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

PEPG - PepGen Inc Latest SEC Filings

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 33.0% Price confirming higher
Trend fit Trend inactive 59.2% over four weeks
Fair value -61.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 40
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
TradingView 9
The National Law Review 7
Market source 6
simplywall.st 4
MT Newswires 3
Seeking Alpha 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 14
Regulatory and legal 7
Analyst action 4

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Investing.com South Africa Direct company coverage

Craig-Hallum initiates PepGen stock coverage with buy rating By Investing.com

Craig-Hallum has initiated coverage on PepGen Inc. (NASDAQ:PEPG) with a buy rating and an $11.00 price target, noting a substantial upside potential from its current trading price of $1.64. The firm sees PepGen's lead drug candidate, PGN-EDODM1, as a high-risk but highly asymmetr

Tone
Positive 67/100
Event
Analyst action
Published
17 Jun 2026 12:13
Source
Investing.com South Africa
Stock Titan Direct company coverage

[EFFECT] PepGen Inc. SEC Filing

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 07:00
Source
Stock Titan
The American Journal of Managed Care® (AJMC®) Direct company coverage

FDA Pauses PepGen’s DMD Drug Trial in the US

Tone
Neutral 50/100
Event
Market update
Published
19 Dec 2024 08:00
Source
The American Journal of Managed Care® (AJMC®)